In last trading session, Tscan Therapeutics Inc (NASDAQ:TCRX) saw 0.31 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $1.24 trading at -$0.07 or -5.34% at ring of the bell on the day assigns it a market valuation of $70.17M. That closing price of TCRX’s stock is at a discount of -681.45% from its 52-week high price of $9.69 and is indicating a premium of 17.74% from its 52-week low price of $1.02. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.27 million shares which gives us an average trading volume of 464.30K if we extend that period to 3-months.

For Tscan Therapeutics Inc (TCRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.12. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.32 in the current quarter.

Tscan Therapeutics Inc (NASDAQ:TCRX) trade information

Upright in the red during last session for losing -5.34%, in the last five days TCRX remained trading in the red while hitting it’s week-highest on Wednesday, 05/14/25 when the stock touched $1.24 price level, adding 15.13% to its value on the day. Tscan Therapeutics Inc’s shares saw a change of -59.21% in year-to-date performance and have moved -2.36% in past 5-day. Tscan Therapeutics Inc (NASDAQ:TCRX) showed a performance of -4.62% in past 30-days. Number of shares sold short was 1.79 million shares which calculate 3.46 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 58.67% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 3. It follows that stock’s current price would drop -141.94% in reaching the projected high whereas dropping to the targeted low would mean a loss of -141.94% for stock’s current value.

Tscan Therapeutics Inc (TCRX) estimates and forecasts

This year revenue growth is estimated to rise 108.72% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.3M for the same. And 5 analysts are in estimates of company making revenue of 1.3M in the next quarter. Company posted 536k and 1.05M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -14.41% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -10.42% while estimates for its earnings growth in next 5 years are of 9.32%.

Tscan Therapeutics Inc (NASDAQ:TCRX)’s Major holders

Insiders are in possession of 0.24% of company’s total shares while institution are holding 87.85 percent of that, with stock having share float percentage of 88.06%. Investors also watch the number of corporate investors in a company very closely, which is 87.85% institutions for Tscan Therapeutics Inc that are currently holding shares of the company. LYNX1 CAPITAL MANAGEMENT LP is the top institutional holder at TCRX for having 5.22 million shares of worth $30.56 million. And as of 2024-06-30, it was holding 4.6062 of the company’s outstanding shares.

The second largest institutional holder is ECOR1 CAPITAL, LLC, which was holding about 5.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.4082 of outstanding shares, having a total worth of $29.25 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and BlackRock Health Sciences Term Trust are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.37 shares of worth $1.7 million or 2.62% of the total outstanding shares. The later fund manager was in possession of 1.05 shares on Dec 31, 2024 , making its stake of worth around $1.3 million in the company or a holder of 2.00% of company’s stock.